Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents-Reference-Cited by-同舟云学术

Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents

Published:2011-01-13 Issue:1 Volume:3 Page:24-33
ISSN:1943-4588
Container-title:Current Breast Cancer Reports
language:en
Short-container-title:Curr Breast Cancer Rep

Author:

Oakman Catherine,Santarpia Libero,Moretti Erica,Biganzoli Laura,Di Leo Angelo

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s12609-010-0033-1.pdf

Reference52 articles.

1. Howell A, Cuzick J, Baum M, et al.: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.

2. Jakesz R, Jonat W, Gnant M, et al.: Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366:455-462.

3. Bonneterr J, Buzdar A, Nabholtz JM, et al.: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: Results of two randomized trials designed for combined analysis. Cancer 2001, 92:2247-2258.

4. Johnston SR, Head J, Pancholi S, et al.: Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 2003, 9(1 Pt 2):524S-32S.

5. • Chia S, Gradishar W, Mauriac L, et al.: Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008, 26:1664-1670. This article provides evidence for fulvestrant efficacy beyond resistance to non-steroidal AI.